Mexidol Safety and Efficacy for Acute Ischemic Stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether Mexidol, a medication that may protect brain tissue, can help people recover better after an acute ischemic stroke (a type of stroke caused by a blood clot). The study includes stroke patients and healthy volunteers to understand how the drug works and if it's safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had your first-ever stroke in the front or middle part of your brain, confirmed by a CT or MRI scan
- Your stroke symptoms started or were last noticed within 36 hours before joining the study
- You were able to do daily activities without help before your stroke (minimal disability)
- Your stroke symptoms are moderate (scored 6–20 on the NIH Stroke Scale, with some arm or leg weakness)
- You are between 18 and 90 years old and able to give informed consent
- You are willing to use effective birth control and abstain from alcohol during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an investigational study drug can improve outcomes after an acute ischemic stroke (a stroke caused by blocked blood flow). You may be eligible if you are able to start treatment quickly after symptom onset and have a moderate stroke severity on a standard stroke exam.
This study tests an investigational drug called Dimephosphon to see if it helps people recover from a recent ischemic stroke (a stroke caused by a clot). It is for adults ages 35–80 whose symptoms began 24 to 72 hours ago and who have not received clot-busting treatments.
This trial tests a new medicine called SP-8203 added to standard clot-busting treatment for people having a moderate to severe stroke. The goal is to see if it helps improve recovery and is safe.
This trial tests a new sublingual tablet (Edaravone Dexborneol) to help people recover after a small stroke caused by disease of the small blood vessels in the brain. It aims to see if the drug can improve thinking and daily function.
This trial tests a new treatment called NXL-001 for people who have had a stroke affecting movement. The goal is to see if it is safe and if it can help improve motor function. It is for those who still have moderate to severe weakness 2-4 months after their stroke.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.